Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-11 | 2024-09 | -0.05 | N/A | N/A | N/A |
2024-08-12 | 2024-06 | -0.05 | -0.05 | N/A | N/A |
2024-05-13 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
2024-04-01 | 2023-12 | -0.05 | -0.06 | -0.01 | -20.00% |
2023-11-13 | 2023-09 | 0 | -0.05 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -0.06 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | Cantor Fitzgerald | Upgrade | Overweight | |
2020-09-16 | Ascendiant Capital | Upgrade | Buy | |
2019-12-17 | Maxim Group | Upgrade | Hold | Buy |
2018-01-25 | Maxim Group | Upgrade | Buy | |
2013-10-06 | Sidoti & Co. | Downgrade | Buy | Neutral |
2013-04-14 | Sidoti & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-03-08 | CHEN SHU-CHIH | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2013-05-14 | CROSS ALEXANDER DENNIS | Director | 0.00 | Purchase |
2024-04-09 | FINN JONATHAN F. | Director | 25.00K | Purchase |
2017-11-14 | GUSE KYLE | General Counsel | 10.00K | Purchase |
2016-03-08 | QUAY STEVEN C | Chief Executive Officer | 0.00 | Purchase |
2017-04-16 | REMMEL H LAWRENCE | Director | 3.13K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 5.68M | 7.15M | 4.51% |
2023-06-29 | Blackrock Inc. | 2.90M | 3.65M | 2.30% |
2023-06-29 | Laurion Capital Management, LP | 2.23M | 2.80M | 1.77% |
2023-06-29 | Geode Capital Management, LLC | 1.11M | 1.40M | 0.88% |
2023-06-29 | Renaissance Technologies, LLC | 1.07M | 1.35M | 0.85% |
2023-06-29 | State Street Corporation | 436.27K | 549.70K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.78M | 4.76M | 3.00% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.66M | 2.10M | 1.32% |
2023-05-30 | Fidelity Extended Market Index Fund | 659.95K | 613.75K | 0.52% |
2023-05-30 | BlackRock Advantage Small Cap Core Fund | 340.50K | 316.67K | 0.27% |
2023-05-30 | Fidelity Total Market Index Fund | 182.91K | 170.11K | 0.15% |
2023-05-30 | Fidelity Series Total Market Index Fund | 142.17K | 132.22K | 0.11% |
Split | Date |
---|---|
1 : 12 | 2018-04-20 |
1 : 15 | 2016-08-26 |
-
I don’t even get mad at SHORTS, everyone has their own method to make money.
-
Because the ones who are too scared to make moves for free shares like to express their anger and frustration by calling them “penny fluppers” when they are actually usually netting thousands every time they swing it.
-
All they have to do is drop the updates that were supposed to have already been released and they could get the YES votes.
-
West Coast taking profit
-
I believe if it looks like the vote isn’t going to pass, they will be forced to release some PR as a last ditch effort. If it looks like it’s gonna pass then no need to...
-
Not gonna see big numbers until we get some PR
-
West Coast traders are stirring
-
Common sense, release the updates and you’d get the YES votes.
-
I voted NO! What shareholder would want to dilute with 15 million shares when they won’t even release promised updates??? You want my vote, give the damn updates!
-
Boom.....
-
TokyoRose is a trooper! Much respect to stick around!
-
NASDAQ is inching up, correction to statement
-
NASDAQ is up
-
Will be 3 bucks soon
-
Tutes aren’t buying with volume this low lol. They already in.
-
Big movement disparities
-
3 bucks around the corner
-
One thing is likely, we won’t get any PR lol. Still waiting on the trials update promised over a month ago
-
Too risky to sell at open hoping for a big dip. Just gonna ride mine out
-
BLACKROCK also loans out its shares to Shorting Firms. Hoping that’s not the case here
-
Atos: contract to reinforce a supercomputer in Sweden
news.google.com • -
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
globenewswire.com • -
3 Dirt-Cheap Drug Developers With Blockbuster Potential
investorplace.com • -
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
investorplace.com • -
Atossa Therapeutics names Heather Rees as CFO
proactiveinvestors.com • -
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
globenewswire.com • -
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
globenewswire.com • -
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
investorplace.com • -
Atossa to Present at the Sidoti Small-Cap Investor Conference
globenewswire.com •